WOBURN, Mass.--(BUSINESS WIRE)--CONTINUUS Pharmaceuticals, a cutting-edge pharmaceutical firm specializing in end-to-end integrated continuous manufacturing, is pleased to announce the appointment of William S. Marth, RPh., MBA to its esteemed Board of Directors.

马萨诸塞州沃本市。-（商业新闻短讯）--CONTINUUS Pharmaceuticals是一家专业从事端到端集成连续制造的尖端制药公司，很高兴宣布任命William S.Marth，RPh。，MBA授予其备受尊敬的董事会。

Mr. Marth brings over three decades of invaluable experience in the global pharmaceutical industry. His deep understanding of the industry is pivotal in ensuring a successful cGMP commercial implementation of CONTINUUS technology and makes him an ideal addition to CONTINUUS’s leadership team.

Marth先生在全球制药行业拥有30多年的宝贵经验。他对行业的深刻理解对于确保cGMP成功商业实施CONTINUUS技术至关重要，并使他成为CONTINUUS领导团队的理想人选。

'It is an exciting opportunity to join the Board of CONTINUUS, a leader in integrated continuous manufacturing of pharmaceuticals. Continuous manufacturing is an important strategic initiative for the pharmaceutical industry and robustness of global supply chains,' said Mr. Marth.

“加入CONTINUUS董事会是一个令人兴奋的机会，CONTINUUS是药品综合连续制造的领导者。马思说，连续制造是制药行业和全球供应链稳健性的重要战略举措。

Mr. Marth serves as the Managing Partner of North Ocean Ventures, LLC as well as President of Services at National Resilience. Prior to that, Mr. Marth led the take private of AMRI now Curia (Nasdaq AMRI) in September of 2017 in a $1.6 billion-dollar transaction after a series of 7 acquisitions in 4 years to build one of the top 5 Global CDMOs.

Marth先生是North Ocean Ventures，LLC的管理合伙人，也是National Resilience的服务总裁。在此之前，Marth先生于2017年9月以16亿美元的交易领导了AMRI now Curia（Nasdaq-AMRI）的私有化，此前他在4年内进行了7次收购，建立了全球五大CDMO之一。

A Director of the company since 2012, Mr. Marth served as President and Chief Executive Officer of AMRI since 2014. He also served as Chairman of the Board in 2013. Prior to joining AMRI, Mr. Marth served as President and CEO of Teva Pharmaceutical Industries Ltd. for the Americas’..

Marth先生自2012年起担任公司董事，自2014年起担任AMRI总裁兼首席执行官。2013年，他还担任董事会主席。在加入AMRI之前，Marth先生曾担任Teva Pharmaceutical Industries Ltd.美洲区总裁兼首席执行官。。

Salvatore Mascia, Chief Executive Officer of CONTINUUS, expressed enthusiasm about Mr. Marth’s appointment: “Having signed several development contracts with major pharma companies, we are at a key stage in the launch of our commercial supply activities, therefore we considered expanding our Board with the necessary skill set to accomplish this goal.

CONTINUUS首席执行官Salvatore Mascia对Marth先生的任命表示了热情：“我们与主要制药公司签署了几份开发合同，目前正处于启动商业供应活动的关键阶段，因此我们考虑用必要的技能扩展董事会，以实现这一目标。

Mr. Marth is undoubtedly the ideal industrial executive to guide us into this new phase of the company. I feel honored to have the opportunity to work and learn from his deep knowledge and experience.”.

毫无疑问，Marth先生是带领我们进入公司新阶段的理想行业高管。我很荣幸有机会工作，并从他深厚的知识和经验中学习。”。

About CONTINUUS Pharmaceuticals: CONTINUUS Pharmaceuticals is a pioneering pharmaceutical company dedicated to revolutionizing drug production. Leveraging innovative technologies, CONTINUUS aims to broaden patients' access to critical medications and improve global health outcomes.

关于CONTINUUS Pharmaceuticals：CONTINUUS Pharmaceuticals是一家开创性的制药公司，致力于彻底改变药物生产。利用创新技术，CONTINUUS旨在扩大患者获得关键药物的机会，并改善全球健康状况。